I know that eviscerate smolder is about 10% less effective than OG eviscerate. Where does this burn free version fall into all this?

With the adjustments I have made to the formula, I have added a new direction to the formula and we have used a non-pungent TRPV1 agonist that should be equally as potent as the pure capsaicin currently used.

It should be equally as potent.

Evolutionary Muse - Inspire to Evolve
BPS - Where Body meets Performance
Flawless Skin Couture - We give you the tools to make you Flawless

With the adjustments I have made to the formula, I have added a new direction to the formula and we have used a non-pungent TRPV1 agonist that should be equally as potent as the pure capsaicin currently used.

It should be equally as potent.

Thanks for the reply! And good to hear! Evomuse doing big things lately!

With the adjustments I have made to the formula, I have added a new direction to the formula and we have used a non-pungent TRPV1 agonist that should be equally as potent as the pure capsaicin currently used.

It should be equally as potent.

Interesting. I'm just about out of my AA. I'll be ready to give this a go!

Intravenous injection of stearoyl vanillylamide (C18-VA), a nonpungent capsaicin (CAP) analog, enhances adrenaline secretion significantly and as effectively as CAP in rats. Because swimming capacity was enhanced by CAP in mice due to CAP-induced adrenal catecholamine secretion, we investigated the effects of oral administration of C18-VA on swimming capacity using an adjustable-current water pool. Male Std ddY 6-wk-old mice were fed a commercial diet for this study and one group was orally administered C18-VA via a stomach tube. Treated mice were able to swim longer before exhaustion than the control mice (62.9 +/- 5.6 vs. 49.6 +/- 7. 0 min, P < 0.05). The swimming capacity of two groups administered C18-VA (0.02 and 0.033 mmol/kg) was significantly greater than that of those administered vehicle alone, (P < 0.05). Substance P concentration in cerebrospinal fluid, which is involved in pain transmission and is the first direct measure of pungency, was not affected by C18-VA administration. In an experiment examining the effects of C18-VA on serum adrenaline concentration, adrenaline was significantly greater in C18-VA treated mice than in controls at 2-h post-dose (C18-VA group, 26.09 +/- 2.82; control group 13.29 +/- 0. 96 microg/L, P < 0.01). In a separate study free fatty acids in serum were elevated in treated mice at 2-h post-dose (P < 0.01). While serum glucose concentration was not affected. These results suggest that C18-VA increased swimming capacity of mice via adrenaline release, independent of pungency. In addition, the present study suggests the usefulness of its application to humans.

PMID:9808652 [PubMed - indexed for MEDLINE

Evolutionary Muse - Inspire to Evolve
BPS - Where Body meets Performance
Flawless Skin Couture - We give you the tools to make you Flawless